Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,038

Document Document Title
WO/2018/132732A1
Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide, where the conjugates have phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of de...  
WO/2018/130834A1
The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.  
WO/2018/124425A1
The present invention relates to a novel peptide, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide, and a pharmaceutical composition, a quasi-drug composition, and a healthy functional food compos...  
WO/2018/115602A1
The present invention relates to therapeutic peptides.  
WO/2018/104922A1
The present invention relates to the efficient solid-phase synthesis of liraglutide represented by Formula-I. The present invention relates to an efficient process for the preparation of liraglutide by sequential coupling employing solid...  
WO/2018/106470A1
The present invention is drawn to compositions and methods for improving transformation frequency. The compositions, synthetic selectable marker genes, are used in transformation methods and result in increased transformation frequency.  
WO/2018/067291A1
Specifically, methods for patient stratification and selection of personalized peptide based treatments and vaccines are disclosed, including assays for identifying antigenic and immunogenic peptides involved in immune responses of mamma...  
WO/2018/048806A1
The present invention provides compounds that are antagonists of CXCR4 and methods for using the same for treatment of a clinical condition associated with CXCR4 activation. In particular, compounds of the invention include cyclic peptid...  
WO/2018/023028A1
Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with synucleinopathy and for measuring synucleinopathy progression or status. Test kits for diagnosis of an indiv...  
WO/2018/005556A1
Provided are methods of identifying peptide epitopes of an antigen recognized by the non-classical major histocompatibility complex (MHC) molecule designated MHC-E. In some embodiments, the antigen is a tumor antigen, autoimmune antigen ...  
WO/2017/219029A3
The invention provides compositions and methods useful for the depletion of CD1 17+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are ...  
WO/2017/190263A1
Provided are derivatives of a snake venom C fragment straight-chain polypeptide and a cyclic peptide related thereto, and a preparation method therefor. The derivatives comprise a parent peptide sequence as shown in formula I: R1-P1-Asp-...  
WO/2017/192460A1
This disclosure relates to isotopically modified amino acids and their pharmaceutical or nutritional uses in stabilizing pharmaceutical protein-based formulations, proteins with long life span, and preventing or treating disease such as ...  
WO/2017/188498A1
An antimicrobial peptide and an antimicrobial peptide composition containing the same, of the present invention, have remarkably higher antimicrobial activity against gram (+) and gram (-) strains than wild type LPcin-I, which has antimi...  
WO/2017/176076A1
The present invention relates to a novel, translationally controlled tumor protein derived-protein transduction domain (TCTP-PTD) having the ability to penetrate the cell membrane, and to the use thereof. The TCTP-PTD peptide of the pr...  
WO/2017/173321A1
The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.  
WO/2017/165617A1
Methods for assessing the efficacy of internally cross-linked p53 transactivation domain-based inhibitor peptides in the treatment of pediatric cancer and methods of using such peptides to treat pediatric cancer are provided.  
WO/2017/158367A1
The present invention relates to novel peptides derived from Progesterone-associated endometrial protein (PAEP), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC...  
WO/2017/150724A1
The present invention provides a novel soybean allergy antigen, a diagnostic method and diagnostic kit for soybean allergies, a pharmaceutical composition including the antigen, a soybean or soybean product in which the antigen has been ...  
WO/2017/115367A1
The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject. The composition a peptid...  
WO/2017/115853A1
A peptide having the following sequence is added as a peptide tag to a useful protein and expressed. Xm(PYn)qPZr Here, X, Y, and Z are amino acid residues each selected independently from R, G, S, K, T, L, N, Q, and H, and at l...  
WO/2017/100199A1
The present invention provides a method for treating a subject afflicted with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: a) admin...  
WO/2017/096036A1
The present disclosure is directed to HER2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or...  
WO/2017/089778A1
The present invention relates to novel peptides derived from Homeobox protein Hox-B13 (HOXB13), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also ...  
WO/2017/089763A1
The present invention relates to novel peptides derived from DDB1 - and CUL4-associated factor 4- like protein 2 (DCAF4L2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in compl...  
WO/2017/089783A1
The present invention relates to novel peptides derived from Prostate specific antigen (KLK3), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also p...  
WO/2017/089773A1
The present invention relates to novel peptides derived from Structural maintenance of chromosomes protein 1 B (SMC1 B), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex ...  
WO/2017/089776A1
The present invention relates to novel peptides derived from Melanoma-associated antigen B2 (MAGEB2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules....  
WO/2017/089765A1
The present invention relates to novel peptides derived from Nuclear receptor subfamily 0 group B member 1 (NR0B1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with ...  
WO/2017/089774A1
The present invention relates to novel peptides derived from Melanoma-associated antigen C (MAGEC1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. ...  
WO/2017/089770A1
The present invention relates to novel peptides derived from melanoma-associated antigen C2 (MAGEC2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules....  
WO/2017/089775A1
The present invention relates to novel peptides derived from Immunoglobulin lambda-like polypeptide 1 (IGLL1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC m...  
WO/2017/089781A3
The present invention relates to novel peptides derived from Abnormal spindle-like microcephaly-associated protein (ASPM), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in comple...  
WO/2017/086090A1
The present invention provides a novel peptide having specific accumulation that acts directly on pancreatic cancer cells and tissues. The present invention is a peptide of (a) or (b) below. (a) A peptide comprising an amino acid sequenc...  
WO/2017/081677A1
The present invention provides a method for the extraction of a phytochemical, e.g., peptide or protein, from a macroalgae by applying pulsed electric field (PEF)- or continuous electric field (CEF)-treatment to said macroalgae in a solv...  
WO/2017/073761A1
Provided are uses for collagen decomposition products or atelocollagen decomposition products having novel physiological functions. A method for forming an embryoid body of pluripotent stem cells according to an embodiment of the present...  
WO/2017/066479A1
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be use...  
WO/2017/055521A3
There is provided agents for modulation of a chronic inflammatory response wherein the agent modulates the biological activity of tenascin, wherein the agents have binding specificity for and/or modulate the biological activity associate...  
WO/2017/055467A1
The present invention relates to polypeptides comprising at least one vinculin binding sites, to nucleic acid sequences encoding thereof and to their use for treating a proliferation and/or adhesion related disease.  
WO/2017/049094A1
Methods for enhancing phytase thermal stability by fusing binding elements to target phytases are provided. Engineered phytases that include binding elements fused to target phytases to cause cyclization of the engineered phytases and en...  
WO/2017/015119A1
Aspects of the disclosure relate to compositions of enzyme-binding polypeptides (EBPs) that modify the substrate specificity of an enzyme and a method for identifying an EBP that modifies substrate specificity of an enzyme binding at lea...  
WO/2017/004811A1
Provided in the application are an active peptide for inhibiting an AMPA receptor and a preparation method and the use thereof. The preparation method for the active peptide comprises the following steps: 1) salmon skin is soaked and the...  
WO/2016/196124A3
The present invention relates to novel prodrugs of primary or secondary amine-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs a...  
WO/2016/179350A1
The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging ag...  
WO/2016/173401A1
Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease, disorder and/or a condition related to inflammation. Also disclosed herein are methods of treating and/or pr...  
WO/2016/164502A1
Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissu...  
WO/2016/147182A1
Disclosed are peptides comprising amino acid residues of the dimer interface of human B7-1 and B7-2 and compositions and uses thereof.  
WO/2016/114992A3
A method of purifying a viral vector is provided. The method includes loading a nonionic density gradient into a continuous flow centrifuge rotor; loading a material including the viral vector into the continuous flow centrifuge rotor; r...  
WO/2016/077413A1
Compositions and kits including an agent that inhibits the interaction between Disabled-2 and mutant CFTR proteins, optionally in combination with a CFTR corrector, CFTR potentiator, CAL inhibitor, mucolytic, anti- inflammatory agent or ...  
WO/2016/057306A1
The present disclosure describes peptide inhibitors of Rho-associtated-kinase (ROCK) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the United States. An inhibitory p...  

Matches 1 - 50 out of 1,038